(Q42174637)

18 October 2017

title

Next generation sequencing of the hepatitis C virus NS5B gene reveals potential novel S282 drug resistance mutations (English)

1 reference

18 October 2017

1 reference

9

Gary Van Domselaar

1 reference

18 October 2017

Hezhao Ji

1

1 reference

18 October 2017

Robert A Kozak

2

1 reference

18 October 2017

Mia J Biondi

3

1 reference

18 October 2017

Richard Pilon

4

1 reference

18 October 2017

Dominic Vallee

5

1 reference

18 October 2017

Ben Binhua Liang

6

1 reference

18 October 2017

David La

7

1 reference

18 October 2017

John Kim

8

1 reference

18 October 2017

Lynne Leonard

10

1 reference

18 October 2017

Paul Sandstrom

11

1 reference

18 October 2017

James Brooks

12

1 reference

18 October 2017

language of work or name

English

0 references

publication date

17 January 2015

1 reference

18 October 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

published in

Virology

1 reference

18 October 2017

volume

477

1 reference

18 October 2017

page(s)

1-9

1 reference

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

18 October 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Selected Replicon Variants with Low-Level In Vitro Resistance to the Hepatitis C Virus NS5B Polymerase Inhibitor PSI-6130 Lack Cross-Resistance with R1479

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Antiviral resistance and direct-acting antiviral agents for HCV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

The presence of resistance mutations to protease and polymerase inhibitors in Hepatitis C virus sequences from the Los Alamos databank

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Naturally occurring dominant drug resistance mutations occur infrequently in the setting of recently acquired hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

No detection of the NS5B S282T mutation in treatment-naïve genotype 1 HCV/HIV-1 coinfected patients using deep sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Resistance to nucleotide analogue inhibitors of hepatitis C virus NS5B: mechanisms and clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Molecular Mechanism of Hepatitis C Virus Replicon Variants with Reduced Susceptibility to a Benzofuran Inhibitor, HCV-796

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Prevalence of amino acid mutations in hepatitis C virus core and NS5B regions among Venezuelan viral isolates and comparison with worldwide isolates.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Pyrosequencing dried blood spots reveals differences in HIV drug resistance between treatment naïve and experienced patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Low abundance drug resistance variants in transmitted HIV drug resistance surveillance specimens identified using tagged pooled pyrosequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

HIV drug resistance surveillance using pooled pyrosequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Dynamics of hepatitis C virus (HCV) RNA-dependent RNA polymerase NS5B in complex with RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Sofosbuvir for previously untreated chronic hepatitis C infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

RG7128 Alone or in Combination with Pegylated Interferon‐α2a and Ribavirin Prevents Hepatitis C Virus (HCV) Replication and Selection of Resistant Variants in HCV‐Infected Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Crystallographic Identification of a Noncompetitive Inhibitor Binding Site on the Hepatitis C Virus NS5B RNA Polymerase Enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Lack of the NS5B S282T mutation in HCV isolates from liver tissue of treatment-naive patients with HCV genotype-1b infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Hepatitis C RNA-dependent RNA polymerase inhibitors: a review of structure-activity and resistance relationships; different scaffolds and mutations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

The Hepatitis C Virus Replicon Presents a Higher Barrier to Resistance to Nucleoside Analogs than to Nonnucleoside Polymerase or Protease Inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Structure of Hepatitis C Virus Polymerase in Complex with Primer-Template RNA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

An update on the management of hepatitis C: consensus guidelines from the Canadian Association for the Study of the Liver

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Re-treatment of chronic hepatitis C virus genotype 1 infection after relapse: an open-label pilot study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Implications of baseline polymorphisms for potential resistance to NS3 protease inhibitors in Hepatitis C virus genotypes 1a, 2b and 3a.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Evidence for separation of HCV subtype 1a into two distinct clades.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Transmission patterns of HIV and hepatitis C virus among networks of people who inject drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Contribution of a mutational bias in hepatitis C virus replication to the genetic barrier in the development of drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Sofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Rapid emergence of protease inhibitor resistance in hepatitis C virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

I-TASSER: a unified platform for automated protein structure and function prediction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

A Canadian screening program for hepatitis C: is now the time?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Infrequent development of resistance in genotype 1-6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Prevalence of hepatitis C virus subgenotypes 1a and 1b in Japanese patients: ultra-deep sequencing analysis of HCV NS5B genotype-specific region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Clinical implications of hepatitis C viral kinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

I-TASSER server for protein 3D structure prediction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

Rapid and simple method for purification of nucleic acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2014.12.037

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VIROL.2014.12.037

1 reference

18 October 2017

1 reference